Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC)

被引：0
|
作者：
Liu, Joyce F.
Fu, Siqing
Richardson, Gary Edward
Vranjes, Zivko
Meniawy, Tarek
Shannon, Catherine M.
Hamilton, Erika P.
Blank, Stephanie V.
Mathews, Cara Amanda
Alidzanovic, Jasmina
Ruseva, Rossitza Krasteva
Shi, Qing
Harismendy, Olivier
Ptaszynski, Ann M.
Westin, Shannon Neville
Meric-Bernstam, Funda
Thaker, Premal H.
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[3] Cabrini Res, Malvern, Australia
[4] Univ Clin Ctr Republ Srpska, Banja Luka, Bosnia & Herceg
[5] Linear Canc Res, Nedlands, WA, Australia
[6] Univ Western Australia, Nedlands, WA, Australia
[7] Mater Adult Hosp Brisbane, South Brisbane, Qld, Australia
[8] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[9] Icahn Sch Med Mt Sinai, New York, NY USA
[10] Women & Infants Hosp Rhode Isl, Providence, RI USA
[11] Univ Clin Ctr Tuzla, Tuzla, Bosnia & Herceg
[12] Uni Hosp Oncol Ctr Panagueristhe, Panagyurishte, Bulgaria
[13] Zentalis Pharmaceut, New York, NY USA
[14] Zentalis Pharmaceut, San Diego, CA USA
[15] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[16] Washington Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5513
引用
收藏
页数：1
相关论文
共 5 条
  • [1] A phase Ib dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer
    Fu, S.
    Pasic, A.
    Richardson, G.
    Vranjes, Z. J.
    Meniawy, T.
    de Jong, P. R.
    Donate, F.
    Samatar, A. A.
    Rodriguez, J.
    Pultar, P.
    Voliotis, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S618 - S618
  • [2] PHASE 1B DOSE-ESCALATION STUDY OF ZN-C3 (WEE1 INHIBITOR) WITH CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER: ZN-C3 PLUS GEMCITABINE ARM
    Thaker, Premal
    Pasic, Anes
    Richardson, Gary
    Vranjes, Zivko
    Prather, Stanislava
    Makris, Lukas
    Misir, Soamnauth
    Pultar, Philippe
    Voliotis, Dimitris
    Fu, Siqing
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A242 - A242
  • [3] Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial
    Yuan, Guangwen
    Zhang, Keqiang
    Zheng, Hong
    Wu, Yan
    Sun, Haolin
    Zhang, Jiajing
    Sun, Xiyang
    Wu, Lingying
    GYNECOLOGIC ONCOLOGY, 2024, 187 : 212 - 220
  • [4] A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML)
    Smith, Catherine Choy
    Vachhani, Pankit
    Garcia-Manero, Guillermo
    Grieselhuber, Nicole Renee
    Murthy, Guru Subramanian Guru
    Bhatia, Astha
    Arora, Jatinder
    Izadi, Hooman
    Fiorino, Anthony
    Rampal, Raajit
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).
    Naumann, R. Wendel
    Braiteh, Fadi S.
    Martin, Lainie P.
    Hamilton, Erika P.
    Diaz, John Paul
    Diab, Sami
    Schilder, Russell J.
    Moroney, John William
    Uyar, Denise
    O'Malley, David M.
    Penson, Richard T.
    DiLea, Clifford
    Palumbo, Michael
    De Almeida, Venita I.
    Matheny, Shannon L.
    Lu, Lin
    Berman, Craig Jerome
    Molina, Arturo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
1